TY - JOUR
AU - Staessen,, J.A.
AB - References 1 Thomas F , Bean K, Guize L, Quentzel S, Argyriadis P, Benetos A. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women. Eur Heart J . 2002 ; 23 : 528 –535 2 J Hypertens . 1999 ; 17 : 151 –183 3 Vasan RS , Larson MG, Leip EP. Impact of high–normal blood pressure on the risk of cardiovascular disease. N Engl J Med . 2001 ; 345 : 1291 –1297 4 Vasan RS , Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency to progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet . 2001 ; 358 : 1682 –1686 5 Neaton JD , Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316099 white men. Arch Intern Med . 1992 ; 152 : 56 –64 6 Staessen JA , Nawrot T, Den Hond E. Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study. Lancet . 2001 ; 357 : 1660 –1669 7 Arch Intern Med . 1997 ; 157 : 2413 –2446 8 Wood D , De Backer G, Faergeman O. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention (European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network). Eur Heart J . 2001 ; 19 : 1434 –1503 9 Staessen JA , Wang JG, Brand E. Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens . 2001 ; 19 : 1349 –1358 10 Port S , Garfinkel A, Boyle N. There is a non-linear relationship between mortality and blood pressure. Eur Heart J . 2000 ; 21 : 1635 –1638 11 N Engl J Med . 2000 ; 342 : 145 –153 12 MacMahon S , Sharpe N, Gamble G. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. J Am Coll Cardiol . 2000 ; 36 : 438 –443 13 Lancet . 2001 ; 358 : 1033 –1041 14 Fletcher A , Spiegelhalter D, Staessen J, Thijs L, Bulpitt C. Implications for trials in progress of publication of positive results. Lancet . 1993 ; 342 : 653 –657 Article PDF first page preview Close This content is only available as a PDF. The European Society of Cardiology
TI - Definition of new targets in cardiovascular prevention from young into old age
JO - European Heart Journal
DO - 10.1053/euhj.2002.3179
DA - 2002-04-01
UR - https://www.deepdyve.com/lp/oxford-university-press/definition-of-new-targets-in-cardiovascular-prevention-from-young-into-94m0Cv3XS0
SP - 507
VL - 23
IS - 7
DP - DeepDyve
ER -